A carregar...
Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer: A meta-analysis
The addition of cetuximab to FOLFIRI or FOLFOX as the first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease. An updated systematic meta-analysis was undertaken to de...
Na minha lista:
| Publicado no: | Medicine (Baltimore) |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wolters Kluwer Health
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5371449/ https://ncbi.nlm.nih.gov/pubmed/28328812 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000006335 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|